Table 1.
Clinical features of 57 patients with H. pylori negative gastric MALT lymphoma.
| Clinical Characteristics | Entire Collective (n = 57) | NGS Collective (n = 35/57) |
|---|---|---|
| Sex (female/ male) | 52.6% (30/57)/47.4% (27/57) | 51.4% (18/35)/48.6% (17/35) |
| Age (median) | 61.8 years (range 36–84) | 65.7 years (range 36–80) |
| H. pylori negativity confirmed by | ||
| Histology | 100% (57/57) | 100% (35/35) |
| PCR for H. pylori | 56.1% (32/57) | 48.6% (17/35) |
| Serology | 35.1% (20/57) | 42.9% (15/35) |
| Breath test | 7% (4/57) | 2.9% (1/35) |
| Stool antigen test | 3.5% (2/57) | - |
| Lugano staging system | ||
| Lugano stage I | 59.6% (34/57) | 62.9% (22/35) |
| Lugano stage II | 17.5% (10/57) | 20% (7/35) |
| Lugano stage IV | 22.8% (13/57) | 17.1% (6/35) |
| MALT IPI status | ||
| Low risk | 47.4% (27/57) | 51.4% (18/35) |
| Intermediate risk | 47.4% (27/57) | 45.7% (16/35) |
| High risk | 5.3% (3/57 | 2.9% (1/57) |
| Further clinical features | ||
| Autoimmune disorder | 3.5% (2/57) | 5.7% (2/35) |
| LDH > upper normal limit | 5.3% (3/57) | 5.7% (2/35) |
| Hepatitis B/C virus | 3.5% (2/57) | none |
| Translocation status | ||
| MALT1 rearrangement | 38.6% (22/57) | 31.4% (11/35) |
| IGH rearrangement | 23.5% (12/51) | 28.1% (9/32) |
| First line treatment | ||
| Chemo-/immunotherapy | 77.2% (44/57) | 71.4% (25/35) |
| Antibiotics (=eradication) | 15.8% (9/57) | 22.9% (8/35) |
| Watch and wait | 3.5% (2/57) | 5.7% (2/35) |
| Radiotherapy | 1.8% (1/57) | - |
| Antiviral therapy hepatitis | 1.8% (1/57 | - |
| Median follow-up time (IQR) | 78.4 months (44.9–112) | 66.5 months (23.9–98.3) |
Abbreviations in chronological order: H. = Helicobacter; PCR = polymerase chain reaction; MALT = mucosa-associated lymphoid tissue; NGS = next generation sequencing, IPI = international prognostic index; LDH = lactate dehydrogenase levels, IQR = interquartile range.